Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS

Atypical hemolytic uremic syndrome (aHUS) is a genetic, life-threatening disease characterized by uncontrolled complement activation, systemic thrombotic microangiopathy (TMA), and vital organ damage. We evaluated the effect of terminal complement blockade with the anti-C5 monoclonal antibody eculiz...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Blood
Autores principales: Cofiell, Roxanne, Kukreja, Anjli, Bedard, Krystin, Yan, Yan, Mickle, Angela P., Ogawa, Masayo, Bedrosian, Camille L., Faas, Susan J.
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society of Hematology 2015
Materias:
Clinical Trials and Observations
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4449039/
https://ncbi.nlm.nih.gov/pubmed/25833956
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2014-09-600411
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares